Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing

Cancer Medicine

Volumn 5, Issue 2, 2016, Pages 337-351

  Jin, Yanliang ^a   Wang, Xingwei ^b   Hu, Shaoyan ^a   Tang, Jingyan ^b   Li, Benshang ^b   Chai, Yihuan ^a  

^a CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute lymphoblastic leukemia; Breakpoint; Childhood; ETV6 RUNX1; Next generation sequencing

Indexed keywords

TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; ONCOPROTEIN; TEL-AML1 FUSION PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BIOINFORMATICS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA FLANKING REGION; ETV6 GENE; ETV6 RUNX1 GENE; FEMALE; GENE FUSION; GENE IDENTIFICATION; GENE TRANSLOCATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; NEXT GENERATION SEQUENCING; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE RISK; RUNX1 GENE; SANGER METHOD; SCHOOL CHILD; BONE MARROW; CHROMOSOME 12; CHROMOSOME 21; CHROMOSOME BREAKAGE; CLONAL EVOLUTION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE ORDER; GENETICS; HIGH THROUGHPUT SEQUENCING; INFANT; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE;

BONE MARROW; CHILD; CHILD, PRESCHOOL; CHROMOSOME BREAKPOINTS; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 21; CLONAL EVOLUTION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; GENE ORDER; GENETIC LOCI; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; TRANSLOCATION, GENETIC;

EID: 85006219583     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.579     Document Type: Article

References (57)

1. Mullighan, C. G., J. Zhang, L. H. Kasper, S. Lerach, D. Payne-Turner, L. A. Phillips, et al. 2011. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471:235-239.
2. Medeiros, B. C. 2009. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360:1787; author reply 1787-1788.
3. Meyer, J. A., J. Wang, L. E. Hogan, J. J. Yang, S. Dandekar, J. P. Patel, et al. 2013a. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat. Genet. 45:290-294.
4. Tzoneva, G., A. Perez-Garcia, Z. Carpenter, H. Khiabanian, V. Tosello, M. Allegretta, et al. 2013. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat. Med. 19:368-371.
5. Inthal, A., P. Zeitlhofer, M. Zeginigg, M. Morak, R. Grausenburger, E. Fronkova, et al. 2012. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia 26:1797-1803.
6. Shah, M. Y., and J. D. Licht 2011. DNMT3A mutations in acute myeloid leukemia. Nat. Genet. 43:289-290.
7. Yan, X. J., J. Xu, Z. H. Gu, C. M. Pan, G. Lu, Y. Shen, et al. 2011. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 43:309-315.
8. Harrison, C. J., A. V. Moorman, C. Schwab, A. J. Carroll, E. A. Raetz, M. Devidas, et al. 2014. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28:1015-1021.
9. Meyer, C., J. Hofmann, T. Burmeister, D. Gröger, T. S. Park, M. Emerenciano, et al. 2013b. The MLL recombinome of acute leukemias in 2013. Leukemia 27:2165-2176.
10. Schnittger, S., C. Eder, S. Jeromin, T. Alpermann, A. Fasan, V. Grossmann, et al. 2013. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 27:82-91.
11. Lane, A. A., B. Chapuy, C. Y. Lin, T. Tivey, H. Li, E. C. Townsend, et al. 2014. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat. Genet. 46:618-623.
12. Pui, C. H., W. L. Carroll, S. Meshinchi, and R. J. Arceci 2011. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29:551-565.
13. Hiebert, S. W., W. Sun, J. N. Davis, T. Golub, S. Shurtleff, A. Buijs, et al. 1996. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol. Cell. Biol. 16:1349-1355.
14. Fuka, G., M. Kauer, R. Kofler, O. A. Haas, and R. Panzer-Grümayer 2011. The leukemia-specific fusion gene ETV6/RUNX1 perturbs distinct key biological functions primarily by gene repression. PLoS ONE 6:e26348.
15. Ford, A. M., C. A. Bennett, C. M. Price, M. C. Bruin, E. R. Van Wering, and M. Greaves 1998. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc. Natl Acad. Sci. USA 95:4584-4588.
16. Hong, D., R. Gupta, P. Ancliff, A. Atzberger, J. Brown, S. Soneji, et al. 2008. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319:336-339.
17. Tsuzuki, S., M. Seto, M. Greaves, and T. Enver 2004. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc. Natl Acad. Sci. USA 101:8443-8448.
18. Ly-Sunnaram, B., C. Henry, V. Gandemer, F. L. Mee, F. Burtin, M. Blayau, et al. 2005. Late ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary event in leukemogenesis. Leuk. Res. 29:1089-1094.
19. Zuna, J., J. Madzo, O. Krejci, Z. Zemanova, M. Kalinova, K. Muzikova, et al. 2011. ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia. Blood 117:368-369; author reply 370-361
20. Kempski, H. M., and N. T. Sturt 2000. The TEL-AML1 fusion accompanied by loss of the untranslocated TEL allele in B-precursor acute lymphoblastic leukaemia of childhood. Leuk. lymphoma 40:39-47.
21. Mangolini, M., J. de Boer, V. Walf-Vorderwülbecke, R. Pieters, M. L. den Boer, and O. Williams 2013. STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia. Blood 122:542-549.
22. Ford, A. M., C. Palmi, C. Bueno, D. Hong, P. Cardus, D. Knight, et al. 2009. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J. Clin. Investig. 119:826-836.
23. Bhojwani, D., D. Pei, J. T. Sandlund, S. Jeha, R. C. Ribeiro, J. E. Rubnitz, et al. 2012. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 26:265-270.
24. Avigad, S., G. Kuperstein, J. Zilberstein, E. Liberzon, B. Stark, I. Gelernter, et al. 1999. TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia. Leukemia 13:481-483.
25. Seeger, K., A. von Stackelberg, T. Taube, D. Buchwald, G. Körner, M. Suttorp, et al. 2001. Relapse of TEL-AML1-positive acute lymphoblastic leukemia in childhood: a matched-pair analysis. J. Clin. Oncol. 19:3188-3193.
26. Tsang, K. S., C. K. Li, K. W. Chik, M. M. Shing, W. C. Tsoi, M. H. Ng, et al. 2001. TEL/AML1 rearrangement and the prognostic significance in childhood acute lymphoblastic leukemia in Hong Kong. Am. J. Hematol. 68:91-98.
27. Shurtleff, S. A., A. Buijs, F. G. Behm, J. E. Rubnitz, S. C. Raimondi, M. L. Hancock, et al. 1995. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 9:1985-1989.
28. Aguiar, R. C., J. Sohal, F. van Rhee, M. Carapeti, I. M. Franklin, A. H. Goldstone, et al. 1996. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. Br. J. Haematol. 95:673-677.
29. Ford, A. M., K. Fasching, E. R. Panzer-Grümayer, M. Koenig, O. A. Haas, and M. F. Greaves 2001. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood 98:558-564.
30. Ding, L., T. J. Ley, D. E. Larson, C. A. Miller, D. C. Koboldt, J. S. Welch, et al. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506-510.
31. Mullighan, C. G., L. A. Phillips, X. Su, J. Ma, C. B. Miller, S. A. Shurtleff, and J. R. Downing 2008. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322:1377-1380.
32. van Delft, F. W., S. Horsley, S. Colman, K. Anderson, C. Bateman, H. Kempski, et al. 2011. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood 117:6247-6254.
33. van Dongen, J. J., T. Seriu, E. R. Panzer-Grümayer, A. Biondi, M. J. Pongers-Willemse, L. Corral, et al. 1998. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731-1738.
34. Zhou, J., M. A. Goldwasser, A. Li, S. E. Dahlberg, D. Neuberg, H. Wang, et al. 2007. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 110:1607-1611.
35. Cave, H., J. van der Werff ten Bosch, S. Suciu, C. Guidal, C. Waterkeyn, J. Otten, et al. 1998. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N. Engl. J. Med. 339:591-598.
36. Coustan-Smith, E., J. Sancho, M. L. Hancock, J. M. Boyett, F. G. Behm, S. C. Raimondi, et al. 2000. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96:2691-2696.
37. Gabert, J., E. Beillard, V. H. van der Velden, W. Bi, D. Grimwade, N. Pallisgaard, et al. 2003. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17:2318-2357.
38. Fronkova, E., J. Madzo, J. Zuna, L. Reznickova, K. Muzikova, O. Hrusak, et al. 2005. TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL. Leukemia 19:1296-1297.
39. Taube, T., C. Eckert, G. Korner, G. Henze, and K. Seeger 2004. Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods. Leuk. Res. 28:699-706.
40. Pallisgaard, N., N. Clausen, H. Schroder, and P. Hokland 1999. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosom. Cancer 26:355-365.
41. Campana, D., and E. Coustan-Smith 2002. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract. Res. Clin. Haematol. 15:1-19.
42. Satake, N., H. Kobayashi, Y. Tsunematsu, H. Kawasaki, Y. Horikoshi, S. Koizumi, and Y. Kaneko 1997. Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21). Br. J. Haematol. 97:607-611.
43. Golub, T. R., G. F. Barker, S. K. Bohlander, S. W. Hiebert, D. C. Ward, P. Bray-Ward, et al. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 92:4917-4921.
44. Wiemels, J. L., F. E. Alexander, G. Cazzaniga, A. Biondi, S. P. Mayer, and M. Greaves 2000. Microclustering of TEL-AML1 translocation breakpoints in childhood acute lymphoblastic leukemia. Genes Chromosom. Cancer 29:219-228.
45. McHale, C. M., J. L. Wiemels, L. Zhang, X. Ma, P. A. Buffler, W. Guo, et al. 2003. Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in California. Genes Chromosom. Cancer 37:36-43.
46. Wiemels, J. L., G. Cazzaniga, M. Daniotti, O. B. Eden, G. M. Addison, G. Masera, et al. 1999. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354:1499-1503.
47. He, Y., J. Wu, D. C. Dressman, C. Iacobuzio-Donahue, S. D. Markowitz, V. E. Velculescu, et al. 2010. Heteroplasmic mitochondrial DNA mutations in norma l and tumour cells. Nature 464:610-614.
48. Wu, J., H. Matthaei, A. Maitra, M. Dal Molin, L. D. Wood, J. R. Eshleman, et al. 2011. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci. Transl. Med. 3:92ra66.
49. Mazloumi, S. H., D. S. Madhumathi, L. Appaji, and Prasannakumari 2012. Combined study of cytogenetics and fluorescence in situ hybridization (FISH) analysis in childhood acute lymphoblastic leukemia (ALL) in a tertiary cancer centre in South India. Asian Pac. J. Cancer Prev. 13:3825-3827.
50. Letouzey, M., D. Penther, C. Roche-Lestienne, B. Nelken, C. Devoldère, J. P. Vannier, and P. Schneider 2014. Detection of dicentric chromosome (9;20) in paediatric B-cell acute lymphoblastic leukaemia: prognostic significance. Ann. Hematol. 94:187-193.
51. Ochman, H., A. S. Gerber, and D. L. Hartl 1988. Genetic applications of an inverse polymerase chain reaction. Genetics 120:621-623.
52. Sanchez, G., X. Xu, J. C. Chermann, and I. Hirsch 1997. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J. Virol. 71:2233-2240.
53. Martineau, M., G. R. Jalali, K. E. Barber, Z. J. Broadfield, K. L. Cheung, J. Lilleyman, et al. 2005. ETV6/RUNX1 fusion at diagnosis and relapse: some prognostic indications. Genes Chromosom. Cancer 43:54-71.
54. Colotta, F., P. Allavena, A. Sica, C. Garlanda, and A. Mantovani 2009. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073-1081.
55. Lengauer, C., K. W. Kinzler, and B. Vogelstein 1998. Genetic instabilities in human cancers. Nature 396:643-649.
56. Kuster, L., R. Grausenburger, G. Fuka, U. Kaindl, G. Krapf, A. Inthal, et al. 2011. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood 117:2658-2667.
57. Panzer-Grümayer, E. R., G. Cazzaniga, V. H. van der Velden, L. del Giudice, M. Peham, G. Mann, et al. 2005. Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection. Clin. Cancer Res. 11:7720-7727.